(1S)-2-methyl-1-phenylprop-2-en-1-amine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (1S)-2-methyl-1-phenylprop-2-en-1-amine
• 化学式: C₁₀H₁₃N
• 分子量: 147.22
• InChiKey: XXZPRXNNZWJBOH-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] ANTIBODY-DRUG CONJUGATES OF TUBULYSIN ANALOGS WITH ENHANCED STABILITY<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENTS D'ANALOGUES DE LA TUBULYSINE À STABILITÉ AMÉLIORÉE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2017196598A1

  公开（公告）日：2017-11-16

  The drug component of an antibody-drug conjugate having a structure according to formula (II), where Ab, m, n, R1, R2, R3, R4, and R5 are as defined in the application, exhibits unexpectedly improved stability.

  抗体药物复合物的药物组分具有按照公式(II)定义的结构，其中Ab、m、n、R1、R2、R3、R4和R5如申请中所定义，表现出意外地提高了稳定性。
• COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
  申请人：BIGGART Agnes

  公开号：US20150175613A1

  公开（公告）日：2015-06-25

  The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.

  本发明提供了Formula A的化合物：或其药学上可接受的盐、互变异构体或立体异构体，其中变量如本文所定义。本发明还提供了包含这种化合物的药物组合物，并使用这种化合物治疗、预防、抑制、改善或根除由寄生虫引起的疾病的病理学和/或症状学的方法，如利什曼病、人类非洲锥虫病和光照病。
• US9303034B2
  申请人：——

  公开号：US9303034B2

  公开（公告）日：2016-04-05
• [EN] PRODRUGGABLE ANTIBODIES, PRODRUGS THEREOF, AND METHODS OF USE AND MAKING<br/>[FR] ANTICORPS SOUS FORME DE PROMÉDICAMENTS, PROMÉDICAMENTS À BASE DE CEUX-CI, LEURS PROCÉDÉS D'UTILISATION ET DE PRÉPARATION
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2019036433A2

  公开（公告）日：2019-02-21

  A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.
• [EN] ANTI-CTLA4 ANTIBODY PRODRUGGABLE (PROBODY) AT A CDR POSITION<br/>[FR] ANTICORPS ANTI-CTLA4 POUVANT ÊTRE TRANSFORMÉ EN PROMÉDICAMENT (PROCORPS) À UNE POSITION CDR
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2020251878A1

  公开（公告）日：2020-12-17

  An anti-CTLA4 antibody can be prodrugged by replacement of certain complementarity determining region (CDR) amino acids with a cysteine (Cys), which provides a chemical functionality for attachment of a blocking moiety that can be cleaved at the site of intended action, thus releasing the un-prodrugged antibody.